Every S-1 that Aspira Womens Health Inc (AWHL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow AWHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AWHL filings page.
Aspira Women’s Health Inc. is registering 16,697,509 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a committed equity purchase arrangement.
The registered shares include up to 15,873,016 shares Aspira may sell to Lincoln Park over 24 months and 824,493 commitment shares already issued as a fee. Aspira will not receive proceeds from Lincoln Park’s resale of these shares, but may raise up to $10.0 million in gross proceeds from its own sales of purchase shares to Lincoln Park, with pricing based on future market prices.
Aspira had 43,480,411 common shares outstanding as of December 29, 2025, including the commitment shares, and estimates 59,353,427 shares would be outstanding if all purchase shares are issued. The stock trades on the OTCQX under the symbol AWHL, where it closed at $0.63 on December 29, 2025.
Aspira Women’s Health filed Amendment No. 1 to a Form S-1 to register the resale of up to 29,226,527 shares of common stock by selling stockholders. The registered shares comprise: 5,915,850 issued on conversion of senior secured convertible notes, 11,848,177 issuable upon exercise of Amended and Restated March 2025 Warrants, 6,550,000 issued under the September 2025 Purchase Agreement, and 4,912,500 issuable upon exercise of September 2025 Warrants.
The company is not selling any securities in this prospectus and will not receive proceeds from stockholder resales. If the Amended and Restated March 2025 Warrants or September 2025 Warrants are exercised for cash, Aspira estimates it would receive $7,831,237. Sales may occur from time to time using methods described under “Plan of Distribution.” Aspira’s common stock trades on the OTCQB as AWHL; the closing price was $0.52 on September 29, 2025. Shares outstanding were 42,655,918 as of September 29, 2025.
Aspira Womens Health Inc. (AWHL) filed a registration statement to register up to 29,226,527 resale shares of its common stock held by selling stockholders. The resale pool comprises shares issued on conversion of convertible notes, shares underlying amended March 2025 warrants, shares issued under a September 2025 purchase agreement, and shares underlying September 2025 warrants. After giving effect to the offering the company expects 59,416,595 shares outstanding based on 42,655,918 shares outstanding as of September 29, 2025. The company will not receive proceeds from the resale by selling stockholders; however, it would receive the nominal cash exercise price if the listed warrants are exercised, estimated at $7,831,237. The prospectus highlights numerous risk factors including limited daily trading volume and concerns about the companys ability to continue as a going concern.